Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Proteomic and oxidative stress analysis in human brain samples of Huntington disease.

Authors: Sorolla, Ma Alba  Reverter-Branchat, Gemma  Tamarit, Jordi  Ferrer, Isidre  Ros, Joaquim  Cabiscol, Elisa 
Citation: Sorolla MA, etal., Free Radic Biol Med. 2008 Sep 1;45(5):667-78. doi: 10.1016/j.freeradbiomed.2008.05.014. Epub 2008 May 28.
Pubmed: (View Article at PubMed) PMID:18588971
DOI: Full-text: DOI:10.1016/j.freeradbiomed.2008.05.014

Huntington disease (HD) is a neurodegenerative disorder caused by expansion of CAG repeats in exon 1 of the huntingtin gene, affecting initially the striatum and progressively the cortex. This work reports a proteomic analysis of human brain postmortem samples obtained from striatum and cortex of patients with HD compared to samples of age- and sex-matched controls. Antioxidant defense proteins that were strongly induced in striatum, but also detectable in cortex, were identified as peroxiredoxins 1, 2, and 6, as well as glutathione peroxidases 1 and 6. The activities of other antioxidant enzymes such as mitochondrial superoxide dismutase and catalase were also increased in HD. Aconitase, a protein involved in energy metabolism, showed decreased activities in striatum of HD patients. Protein carbonyls, used as markers of oxidative stress, were increased in HD, and glial fibrillary acidic protein, aconitase, gamma-enolase, and creatine kinase B were identified as the main targets. Taken together, these results indicate that oxidative stress and damage to specific macromolecules would participate in the disease progression. Also, these data support the rationale for therapeutic strategies that either potentiate antioxidant defenses or avoid oxidative stress generation to delay disease progression.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 13432193
Created: 2017-09-25
Species: All species
Last Modified: 2017-09-25
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.